Brokerages Anticipate Zynerba Pharmaceuticals Inc (ZYNE) Will Announce Earnings of -$0.67 Per Share

Share on StockTwits

Analysts predict that Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) will announce earnings per share of ($0.67) for the current quarter, Zacks reports. Zero analysts have made estimates for Zynerba Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.61) and the lowest estimate coming in at ($0.73). Zynerba Pharmaceuticals reported earnings per share of ($0.60) during the same quarter last year, which would suggest a negative year-over-year growth rate of 11.7%. The business is expected to report its next earnings report on Monday, March 11th.

According to Zacks, analysts expect that Zynerba Pharmaceuticals will report full-year earnings of ($2.87) per share for the current year, with EPS estimates ranging from ($2.94) to ($2.79). For the next fiscal year, analysts anticipate that the company will report earnings of ($2.43) per share, with EPS estimates ranging from ($2.77) to ($1.84). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Zynerba Pharmaceuticals.

Several research firms have recently issued reports on ZYNE. Zacks Investment Research cut Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, January 27th. Cantor Fitzgerald set a $21.00 target price on Zynerba Pharmaceuticals and gave the company a “buy” rating in a report on Monday, December 17th. HC Wainwright set a $23.00 target price on Zynerba Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, November 13th. Finally, ValuEngine cut Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, February 4th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. Zynerba Pharmaceuticals has an average rating of “Hold” and an average price target of $15.88.

Shares of ZYNE stock traded down $0.11 during mid-day trading on Friday, hitting $5.22. 531,395 shares of the company’s stock were exchanged, compared to its average volume of 1,026,503. Zynerba Pharmaceuticals has a fifty-two week low of $2.75 and a fifty-two week high of $12.50. The stock has a market capitalization of $91.15 million, a price-to-earnings ratio of -2.10 and a beta of 4.98.

A number of institutional investors have recently modified their holdings of the stock. Raymond James & Associates acquired a new position in shares of Zynerba Pharmaceuticals during the second quarter worth about $164,000. Millennium Management LLC lifted its stake in shares of Zynerba Pharmaceuticals by 116.0% during the second quarter. Millennium Management LLC now owns 224,511 shares of the company’s stock worth $2,187,000 after purchasing an additional 120,570 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Zynerba Pharmaceuticals during the second quarter worth about $239,000. Engineers Gate Manager LP lifted its stake in shares of Zynerba Pharmaceuticals by 179.8% during the third quarter. Engineers Gate Manager LP now owns 66,270 shares of the company’s stock worth $541,000 after purchasing an additional 42,583 shares in the last quarter. Finally, Zeke Capital Advisors LLC acquired a new position in shares of Zynerba Pharmaceuticals during the third quarter worth about $193,000. Hedge funds and other institutional investors own 15.32% of the company’s stock.

Zynerba Pharmaceuticals Company Profile

Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.

Featured Article: How To Calculate Debt-to-Equity Ratio

Get a free copy of the Zacks research report on Zynerba Pharmaceuticals (ZYNE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply